| scholarly article | Q13442814 |
| P50 | author | Jonathan D Licht | Q42315828 |
| P2093 | author name string | Daphné Dupéré-Richer | |
| P2860 | cites work | MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. | Q51358936 |
| Aberrant p15, p16, p53, and DAPK Gene Methylation in Myelomagenesis: Clinical and Prognostic Implications. | Q51513050 | ||
| NSD1 encoding a histone methyltransferase exhibits frameshift mutations in colorectal cancers. | Q53135777 | ||
| DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell Tumors | Q58050763 | ||
| Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma | Q61905662 | ||
| Global hypomethylation in myeloma is associated with poor prognosis | Q85211662 | ||
| Epigenetic identification of ZNF545 as a functional tumor suppressor in multiple myeloma via activation of p53 signaling pathway | Q89379152 | ||
| Three proteins define a class of human histone deacetylases related to yeast Hda1p | Q22009464 | ||
| Crystal structure of the nucleosome core particle at 2.8 A resolution | Q22122355 | ||
| Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4 | Q24294656 | ||
| G9a and Glp methylate lysine 373 in the tumor suppressor p53 | Q24298004 | ||
| The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress | Q24301895 | ||
| ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage | Q24306743 | ||
| The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα | Q24339204 | ||
| Point mutations in the WD40 domain of Eed block its interaction with Ezh2. | Q24522690 | ||
| Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes | Q24536045 | ||
| Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways | Q24548256 | ||
| NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes | Q24615626 | ||
| Initial genome sequencing and analysis of multiple myeloma | Q24629117 | ||
| Lysine acetylation: codified crosstalk with other posttranslational modifications | Q24644959 | ||
| Involvement of histone H1 in the organization of the nucleosome and of the salt-dependent superstructures of chromatin | Q24681606 | ||
| Structural basis of EZH2 recognition by EED | Q27648788 | ||
| Crystal structure of globular domain of histone H5 and its implications for nucleosome binding | Q27732024 | ||
| Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 | ||
| Role of histone H3 lysine 27 methylation in Polycomb-group silencing | Q28131795 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers | Q28257103 | ||
| SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 | Q28269618 | ||
| DNA methyltransferases and methyl-binding proteins of mammals | Q28279394 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| HDAC6-p97/VCP controlled polyubiquitin chain turnover | Q28507283 | ||
| ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state | Q28594320 | ||
| Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) | Q29147438 | ||
| Selective inhibition of tumor oncogenes by disruption of super-enhancers | Q29617301 | ||
| Risk of tumorigenesis in overgrowth syndromes: A comprehensive review | Q30040907 | ||
| DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling | Q30355347 | ||
| Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial | Q33167710 | ||
| Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. | Q33384994 | ||
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Q33417762 | ||
| Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment | Q33428098 | ||
| Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study | Q33431391 | ||
| The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate | Q33553524 | ||
| Whole-genome fingerprint of the DNA methylome during human B cell differentiation | Q33727500 | ||
| Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma | Q33854012 | ||
| Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer | Q33865946 | ||
| Haploinsufficiency of NSD1 causes Sotos syndrome | Q34118696 | ||
| Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation | Q34133622 | ||
| A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells | Q34302726 | ||
| Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. | Q34460989 | ||
| Epigenetics. Restricted epigenetic inheritance of H3K9 methylation. | Q34470100 | ||
| Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation | Q34479533 | ||
| Genomic complexity of multiple myeloma and its clinical implications | Q34537571 | ||
| The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. | Q34568855 | ||
| The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia | Q35140239 | ||
| Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage | Q35164644 | ||
| SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability | Q35188529 | ||
| NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming | Q35569571 | ||
| Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma | Q35764582 | ||
| Mapping the interaction surface of linker histone H1(0) with the nucleosome of native chromatin in vivo | Q35792693 | ||
| Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies | Q35820972 | ||
| Identification of two DNA-binding sites on the globular domain of histone H5. | Q35900412 | ||
| A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice. | Q35949908 | ||
| Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis | Q36089332 | ||
| Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma | Q36178810 | ||
| Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. | Q36204839 | ||
| Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. | Q36214527 | ||
| Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma | Q36335870 | ||
| The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival | Q36506849 | ||
| H1 linker histone promotes epigenetic silencing by regulating both DNA methylation and histone H3 methylation | Q36583183 | ||
| Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. | Q36835530 | ||
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation | Q36926825 | ||
| Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. | Q37006888 | ||
| The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. | Q37443338 | ||
| Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma | Q37475389 | ||
| Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma | Q37533656 | ||
| EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. | Q37705811 | ||
| Functions of DNA methylation and hydroxymethylation in mammalian development | Q38099074 | ||
| An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. | Q38718859 | ||
| EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes | Q38817953 | ||
| Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma | Q38895976 | ||
| H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer | Q38906678 | ||
| Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death | Q38906685 | ||
| SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. | Q38993472 | ||
| Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. | Q39012832 | ||
| Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma | Q39021479 | ||
| The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer | Q39134084 | ||
| Histone H4 deacetylation facilitates 53BP1 DNA damage signaling and double-strand break repair | Q39208600 | ||
| Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial | Q39280492 | ||
| Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis. | Q39573037 | ||
| Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. | Q39834255 | ||
| Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation | Q40414530 | ||
| An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair | Q40541541 | ||
| Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. | Q40633414 | ||
| Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. | Q40914883 | ||
| Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer | Q41942526 | ||
| Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma | Q42696493 | ||
| Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice. | Q42698125 | ||
| Concerted activities of distinct H4K20 methyltransferases at DNA double-strand breaks regulate 53BP1 nucleation and NHEJ-directed repair | Q42793535 | ||
| NSD1 mutations generate a genome-wide DNA methylation signature. | Q43102156 | ||
| Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency | Q43194593 | ||
| SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma | Q44232582 | ||
| Differential repetitive DNA methylation in multiple myeloma molecular subgroups. | Q45966859 | ||
| TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. | Q46026571 | ||
| DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies | Q47340953 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 336-344 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Current Opinion in Hematology | Q15757961 |
| P1476 | title | Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma | |
| P478 | volume | 24 |
| Q46027484 | Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. |
| Q90266389 | Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations? |
| Q90383109 | Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? |
| Q92429871 | PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation |
| Q93032482 | Regulatory mechanisms of B cell responses and the implication in B cell-related diseases |
| Q60960086 | The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response |
| Q91229404 | The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies |
| Q47101382 | The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains |
Search more.